LY 334370

Drug Profile

LY 334370

Latest Information Update: 25 Jul 2000

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antimigraines; Benzamides; Indoles; Neuroprotectants; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Migraine

Most Recent Events

  • 25 Jul 2000 A study has been added to the therapeutic trials and adverse events sections
  • 23 Jul 1999 A study has been added to the therapeutic trials section
  • 07 Jul 1999 Clinical data have been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top